California State Teachers Retirement System Sells 67,702 Shares of Abbott Laboratories $ABT

California State Teachers Retirement System decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 2.5% during the 1st quarter, HoldingsChannel reports. The fund owned 2,675,057 shares of the healthcare product maker’s stock after selling 67,702 shares during the period. California State Teachers Retirement System’s holdings in Abbott Laboratories were worth $274,648,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. J. Stern & Co. LLP boosted its stake in shares of Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $2,938,892,000. Arrowstreet Capital Limited Partnership raised its holdings in Abbott Laboratories by 217.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock valued at $566,967,000 after buying an additional 3,780,402 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Abbott Laboratories by 303.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after buying an additional 3,330,368 shares during the period. Finally, Ninety One UK Ltd acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $336,815,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Quarterly beat and raised guidance support investor confidence. Abbott reported second-quarter earnings of $1.31 per share, above the $1.28 consensus estimate, while revenue rose 13% year over year to $12.59 billion. Management raised its fiscal 2026 EPS outlook to $5.45-$5.60 and expects third-quarter EPS of $1.38-$1.46. Strong demand for cancer diagnostics and medical devices helped offset concerns about procedure volumes. Abbott Raised Its Profit Forecast
• Positive Sentiment: Growth initiatives provide multiple expansion paths. Abbott is investing in diabetes care, oncology diagnostics and cardiovascular devices through new product launches and acquisitions, giving investors several potential sources of future sales growth. Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends
• Positive Sentiment: New colorectal cancer screening rights strengthen Abbott’s diagnostics portfolio. Abbott secured exclusive U.S. commercialization rights for Freenome’s FDA-cleared SimpleScreen blood-based colorectal cancer test. The product could broaden screening access, particularly among Americans overdue for testing, although commercial adoption will determine the financial impact. FDA Approves Freenome’s SimpleScreen CRC Test
• Neutral Sentiment: Analysts remain constructive but see limited valuation upside. UBS lowered its ABT price target from $135 to $125 while maintaining a Buy rating, implying meaningful upside from the referenced trading level. Another analysis noted that Abbott’s earnings setup has improved, but its elevated valuation could constrain returns. UBS Abbott Price Target Update
• Negative Sentiment: Guidance and litigation concerns remain overhangs. Despite the earnings beat and improved outlook, investors continue to monitor legal risks and whether projected growth will justify Abbott’s premium earnings multiple. Abbott Fell as Guidance and Litigation Concerns Overshadowed Growth

Analyst Ratings Changes

Several equities analysts have issued reports on ABT shares. Bank of America decreased their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. JPMorgan Chase & Co. boosted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Argus decreased their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Piper Sandler reaffirmed an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Oppenheimer reduced their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $118.17.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $107.34 on Wednesday. The business has a 50-day moving average price of $92.32 and a two-hundred day moving average price of $100.85. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market cap of $186.97 billion, a P/E ratio of 34.74, a PEG ratio of 2.02 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the previous year, the business earned $1.26 EPS. The firm’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.